Evaluation of a Standardized Protocol for Thrombin Generation Assay

Study Overview
=================
Brief Summary
-----------------
This study is aims at determining the inter laboratory variation when using the thrombin generation assay calibrated automated thrombogram (TGA CAT). It is thus, not a clinical trial in its usual meaning. However, to achieve relevant test samples one patient will be treated with two different study drugs as part of the trial and therefore, approval by Läkemedelsverket is needed. Test plasma samples will be sent out to five participating centers in the Scandinavian countries (Gothenburg and Stockholm, Sweden, Århus Denmark, Oslo Norway and Helsinki Finland) and coefficients of variance (CV) and level of agreement will be analyzed. To obtain representative plasma samples with a wide range of thrombin generation capacity (TGC), blood samples will be collected from research persons that has given informed consent to participate in the study. To obtain plasma with low TGC, blood samples will be drawn from patients with severe hemophilia (n=4)(study group 1), to obtain plasma with normal TGC, blood samples will be drawn from healthy volunteers (n=3)(study group 2) and to obtain plasma with high TGC, plasma will be collected from healthy volunteers (n=3)(study group 3) that at previous measurements have been shown to have a TGC>2SD of the median of the control population. Moreover, one patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions (Treated HA person). By taking repeated blood samples after administration, samples with a wide range of FVIII levels and TGC:s will be obtained. Moreover, the effect of using plasmas with low, normal and high TGC for normalization will be investigated. Plasma samples will be collected as soon as approval from the Swedish medical agency (SMA) has been obtained, we count on sending them to participating centers March 2017. All laboratory measurements, data analysis and report writing will be concluded before December 31 2017.

Detailed Description
-----------------
Main goal The aim is to further improve the inter-laboratory variability for the TGA-CAT (Thrombin generation assay-calibrated automated thrombogram) method by using an elaborate standardization protocol and in extension making the use of large prospective multi-center studies a reality. Goals of the project are: To determine the inter-laboratory variability by evaluating an enhanced standardized TGA-CAT protocol. To evaluate if the inter-laboratory variability of the TGA-CAT method is effected by administration of a recombinant FVIII product (Advate) in a person with severe hemophilia A To evaluate if the inter-laboratory variability of the TGA-CAT method is effected by administration of a long acting FVIII product (Adynovate) in a person with severe hemophilia A To evaluate three reference plasma´s ability, through normalization of data, to improve the lab-to-lab variability. Introduction The TGA CAT method has proved its usefulness for multiple purposes including diagnosis and management of bleeding disorders (1, 2), detecting hyper coagulability (3, 4), and monitoring and characterization of oral anticoagulant drugs (5, 6). Most of these studies are single-center studies and large prospective multi-center studies are needed to further validate the results. These multi-center studies have proved to be hard to produce due to lack of standardization of the method. In the last couple of years several articles have addressed the problem with large inter-laboratory variability for the TGA-CAT method by presenting thoroughly worked-out standardization protocols. Focus has been put both on the method itself and its pre-analytical factors as well as the usage of reference plasmas (RP) for normalization of results. One article showed that the choice of RP for the normalization of results could greatly reduce the inter-lab variability and that certain RP have a better ability to do so (7). Lately a number of recombinant Factor VIII (rFVIII) and IX (rFIX) drugs with prolonged half-life have been developed and are about to or even have reached the market. The length of the pro-longed activity of the drug differs between patients and a need for individual tailoring of the patient´s drug administration is obvious. Thrombin generation could prove to be an excellent tool in tailoring the optimal drug administration and monitoring the effect of the drug for each individual. Methods and materials Thrombin generation Thrombin generation will be measured according to the method described by Hemker et al.(8): calibrated automated thrombogram (CAT, Thrombinoscope BV, Maastricht, the Netherlands). Reagents PPP-reagent LOW (1 pM), PPP-reagent (5 pM), Thrombin Calibrator and FluCa-kit (TS31.00, TS30.00, TS20.00 and TS50.00, Thrombinoscope BV, Maastricht, The Netherlands) will be used in the test. Samples Three different plasmas will be tested, normal plasma, hypo- and hypercoagulable plasma. Normal and hypercoagulable plasma will be pooled from 3 donors and hypocoagulable plasma will be collected from 4 donors. Hypocoagulable plasma will be collected from five haemophilia A (HA) patients regularly treated at the Malmö Coagulation Unit by taking 10 4.5 mL tubes of citrated blood at one occasion. Normal plasma will be collected from 3 co-workers at the same unit, each person donating 13 tubes of 4.5 mL citrated blood. Hypercoaguable plasma will be prepared from 3 healthy volunteers, shown to have TGA CAT parameter values >2 SD of median by taking 13 tubes of 4.5 mL citrated blood. Plasma from one patient with severe HA patient that have been given FVIII-concentrates, Advate™ respectively the long-acting Adynovate™ at two separate occasions will also be tested. After informed consent the patient will be asked not to take his regular profylaxis dose for 72 hours. The patient will be given Advate™ and Adynovate™ respectively at 30 U/kg. The monitoring samples will be taken 1h, 8h, 24h, 36h and 48h (Advate™) and 1h, 24h, 36h, 48h and 72h (Adynovate™) after injection. At each time point 3 tubes of 4.5 mL blood will be taken. Reference plasmas Siemens Control Plasma P diluted 1:5 will be used as hypocoaguable RP, HemosIL calibration plasma (Instrumentation Laboratory, Bedford, Ma, USA) will be used as Standard RP and as hypercoagable plasma PS-DP (protein S-deficiency plasma)(Enzyme research laboratories, South Bend, In, USA) will be used. Statistical analysis Raw data will be collected and analyzed at the Coagulation Unit, Skåne University Hospital, Malmö. Each participating center will be matched with Malmö Coagulation unit in a test of agreement where Bland-Altman bias plot will be used. The mean, standard deviation (SD) and coefficient of variation (CV%) will be calculated for each center with and without normalization and displayed in a table. The Advate/ Adynovate elimination profiles will be plotted and multivariate repeated measurements analyses of variance including a general test for parallel curves, will be applied to evaluate differences between Centers in the elimination profiles. Study design The study aims to evaluate the inter-laboratory variability of TGA-CAT performed TGT with a highly standardized protocol, how the use of RFs for normalization of data impact on variability of results and to evaluate the usefulness of TGA-CAT in monitoring prolonged FVIII drug administration. All Fluorometers of the participating center´s should be serviced and have temperature calibrated to 37 C prior start of the study. The latest software version must be installed (Thromboscope BV, Maastricht, The Netherlands, version V5.0.0.742). All laboratory equipment, pipettes, water baths, water purifiers, etc., needs to be calibrated. All plasmas, TGA-CAT reagents needed for the study will be administered and distributed to all participating centers by the Coagulation Unit, Malmö. An USB-memory stick containing a plate set-up scheme file and a video file covering critical pre-analytical and analytical steps will also be provided alongside the samples and reagents. Three pooled plasmas (normal, hypo- and hypercoaguable), three RF, five Adynovate and five Advate monitoring samples will be run five times on five different days by each participating center, following a scheme provided in the USB-memory stick, with two different triggers, PPP-reagent LOW (1 pM) and PPP-reagent (5 pM). Two test runs are scheduled each day to maximize RF and reagent usage. The reason for testing three different types of RF is the fact an earlier study results implied a better reduction of variability when using, for an example a hypocoaguable RF to hypocoaguable plasmas (9).

Official Title
-----------------
Calibrated Automated Thrombogram: A Scandinavian Multicenter Study

Conditions
-----------------
Hemophilia A

Intervention / Treatment
-----------------
* Diagnostic Test: Thrombin Generation Assay
* Drug: Treatment with recombinant coagulation factor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For patients with severe hemophilia A (study group 1)(n=4) that has not received any factor concentrate within 72 hours: Diagnosis of severe hemophilia, with regular check-ups at the hemophilia center at SUS, Malmö and willingness to participate For healthy controls (n=3) (study group 2): Willingness to participate For healthy controls with a documented high TGC (study group 3): Willingness to participate Exclusion Criteria For patients with severe hemophilia A (study group 1)(n=4) that has not received any factor concentrate within 72 hours: Intake of any other pharmaceutical product known to have an effect on the coagulation system the last 14 days, to the judgement of the including investigator For healthy controls (n=3) (study group 2): Any disorder known to affect the coagulation system and intake of any drug known to affect the coagulation system the last 14 days before blood sampling , to the judgement of the including investigator. For healthy controls with a documented high TGC (study group 3): Any disorder known to affect the coagulation system and intake of any drug known to affect the coagulation system within the last 14 days before blood sampling, to the judgement of the including investigator.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group 1<br>Patients with severe hemophilia A | Diagnostic Test: Thrombin Generation Assay<br>* Inter lab variation and level of agreement will be determined<br>|
| Study group 2<br>Healthy volunteers | Diagnostic Test: Thrombin Generation Assay<br>* Inter lab variation and level of agreement will be determined<br>|
| Study group 3<br>Healthy volunteers ) that at previous measurements have been shown to have a TGC>2SD of the median of the control population. | Diagnostic Test: Thrombin Generation Assay<br>* Inter lab variation and level of agreement will be determined<br>|
| Treated HA person<br>One patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions | Diagnostic Test: Thrombin Generation Assay<br>* Inter lab variation and level of agreement will be determined<br>Drug: Treatment with recombinant coagulation factor<br>* To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inter lab variability | Coefficient of Variation (CV) i plasma samples with high, normal and low thrombin genration capacity | May 2017 | 
| Inter lab variability | Coefficient of Variation (CV) i plasma samples from a patient treated with Advate | May 2017 | 
| Inter lab variability | Coefficient of Variation (CV) and level of agreement i plasma samples from a patient treated with Adynovate | May 2017 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inter lab variability | Coefficient of Variation (CV) and level of agreement when results have been noramlized with plasma with high, normal and low thrombin generation capacity | May 2017 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemophilia, Thrombin generation, variability, level of agreement